Local recurrence following treatment for breast cancer with an endoscopic nipple-sparing mastectomy

• Published in: Breast cancer (Tokyo, Japan) Japan), 2016-07, Vol.23 (4), p.552-560
• Main Authors: Sakamoto, Naomi, Fukuma, Eisuke, Teraoka, Ko, Hoshi, Kazuei
• Format: Article
• Language: English
• Subjects: Adult; Breast cancer; Breast Neoplasms - pathology; Breast Neoplasms - surgery; Cancer; Cancer Research; Care and treatment; Diseases; Drug therapy; Endoscopy - instrumentation; Endoscopy - methods; Female; Humans; Mastectomy, Subcutaneous - methods; Medical records; Medicine; Medicine & Public Health; Metastasis; Middle Aged; Neoplasm Recurrence, Local - pathology; Nipples - surgery; Oncology; Original Article; Patient satisfaction; Relapse; Retrospective Studies; Sentinel Lymph Node Biopsy; Surgery; Surgical Flaps; Surgical Oncology; Treatment Outcome
• ISSN: 1340-6868; 1880-4233
• DOI: 10.1007/s12282-015-0600-4

Purpose Endoscopic nipple-sparing mastectomy (E-NSM) has been reportedly associated with smaller scars and greater patient satisfaction; however, long-term results of this procedure have not been made. The purpose of this retrospective study was to investigate the local recurrence (LR) rate and factors associated with it after E-NSM and to examine the oncologic safety of this procedure. Methods We reviewed the medical records of a total of 421 breasts in 404 patients who underwent E-NSM to investigate the LR rate and the factors associated with it. The clinico-pathological features and the treatment and outcomes of the patients with LRs were also examined. Results Eleven breasts (2.6 %) in 11 patients presented with LR as the first site of recurrence after a median follow-up time of 61 months. Among the 11 LRs, 9 patients presented with LR only, 1 patient exhibited regional lymph node recurrence, and 1 patient exhibited distant metastasis. The median time from surgery until LR was 25 months. Eight LRs developed near the original tumor site. The risk factors for LR in a multivariate analysis were a younger age of less than 40 years ( p  = 0.02), Stage III tumor ( p  = 0.01), and an inadequate surgical margin ( p  = 0.001). After the treatment, 6 patients had no evidence of disease, 2 patients died from metastatic disease, 2 patients experienced repeat LR, and the remaining patient who rejected excision exhibited a persistent LR. Conclusions E-NSM is an oncologically safe procedure and an acceptable method in selected patients requiring a mastectomy.